Future directions in non-small cell lung cancer

J. H. Schiller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown additive or synergistic effects against tumor tissue. The cytoprotectant amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) is being assessed for its protection of normal tissue against the toxic effects of chemotherapy and radiotherapy and for its potential role in enhancing the efficacy of these modalities. Protection from dose-limiting toxicities may allow dose escalation and improve the therapeutic index. Current and future investigations of novel agents and modalities, with or without cytoprotectants, should lead to better prognosis and prolonged survival rates.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
StatePublished - 1999

Fingerprint

Amifostine
Non-Small Cell Lung Carcinoma
Radiotherapy
Poisons
Cytotoxins
Clinical Trials
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Direction compound
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Schiller, J. H. (1999). Future directions in non-small cell lung cancer. Seminars in Oncology, 26(2 SUPPL. 7), 120-124.

Future directions in non-small cell lung cancer. / Schiller, J. H.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 120-124.

Research output: Contribution to journalArticle

Schiller, JH 1999, 'Future directions in non-small cell lung cancer', Seminars in Oncology, vol. 26, no. 2 SUPPL. 7, pp. 120-124.
Schiller JH. Future directions in non-small cell lung cancer. Seminars in Oncology. 1999;26(2 SUPPL. 7):120-124.
Schiller, J. H. / Future directions in non-small cell lung cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2 SUPPL. 7. pp. 120-124.
@article{c1272af571014cb58faf072783705b41,
title = "Future directions in non-small cell lung cancer",
abstract = "Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown additive or synergistic effects against tumor tissue. The cytoprotectant amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) is being assessed for its protection of normal tissue against the toxic effects of chemotherapy and radiotherapy and for its potential role in enhancing the efficacy of these modalities. Protection from dose-limiting toxicities may allow dose escalation and improve the therapeutic index. Current and future investigations of novel agents and modalities, with or without cytoprotectants, should lead to better prognosis and prolonged survival rates.",
author = "Schiller, {J. H.}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "120--124",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Future directions in non-small cell lung cancer

AU - Schiller, J. H.

PY - 1999

Y1 - 1999

N2 - Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown additive or synergistic effects against tumor tissue. The cytoprotectant amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) is being assessed for its protection of normal tissue against the toxic effects of chemotherapy and radiotherapy and for its potential role in enhancing the efficacy of these modalities. Protection from dose-limiting toxicities may allow dose escalation and improve the therapeutic index. Current and future investigations of novel agents and modalities, with or without cytoprotectants, should lead to better prognosis and prolonged survival rates.

AB - Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown additive or synergistic effects against tumor tissue. The cytoprotectant amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) is being assessed for its protection of normal tissue against the toxic effects of chemotherapy and radiotherapy and for its potential role in enhancing the efficacy of these modalities. Protection from dose-limiting toxicities may allow dose escalation and improve the therapeutic index. Current and future investigations of novel agents and modalities, with or without cytoprotectants, should lead to better prognosis and prolonged survival rates.

UR - http://www.scopus.com/inward/record.url?scp=0032990309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032990309&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 120

EP - 124

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -